Previous 10 | Next 10 |
I-Mab Announces IND Approval by FDA to Initiate Phase 1 Study for Protollin for the Treatment of Alzheimer's Disease PR Newswire Planning underway for a Phase 1 Trial to assess new immunotherapy aimed at stimulating the innate immune system to clear beta amyloid prot...
I-Mab Announces Authorization of a Renewed Stock Repurchase Program by the Company up to US$40 Million PR Newswire SHANGHAI and GAITHERSBURG, Md. , July 29, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical ...
I-Mab Announces IND Acceptance for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China PR Newswire Efineptakin alfa in combination with pembrolizumab induced 27.8% ORR in metastatic TNBC patients in a phase 1b /2 trial in South ...
I-Mab Announces Preliminary Proposal for Potential Dual Listing on the STAR Market of the Shanghai Stock Exchange PR Newswire SHANGHAI and GAITHERSBURG, Md. , July 27, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopha...
naphtalina/iStock via Getty Images I-Mab ([[IMAB]] -14.6%) shares have lost more than a tenth to reach the lowest level since May amid investor concerns that a potential regulatory crackdown targeting for-profit education companies in China could happen with other sectors too. Commenting...
Keymed Biosciences of Chengdu completed a $378.5 million Hong Kong IPO to develop its portfolio of antibody candidate. I-Mab announced two partnerships to develop oncology candidates with China biopharmas that offer novel discovery technologies. Eucure Biopharma has been approved ...
I-Mab (IMAB) announces the signing of two new collaborations with emerging biotech companies in China to strengthen its pipeline.The collaborations are with Immorna, an mRNA biotech company, and neoX Biotech, an AI-enabled R&D biotech company.I-Mab will be developing novel ...
I-Mab Expands Emerging Portfolio of Next Generation Novel Oncology Therapeutics Through Cutting-Edge mRNA and AI Technology Platforms PR Newswire SHANGHAI and GAITHERSBURG, Md. , July 9, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical st...
BeiGene of Beijing has been approved to stage a $3 billion IPO on the Shanghai Star Stock Exchange. Zentalis Pharma, a US-China biopharma, closed a $150 million secondary offering to advance its small molecule cancer portfolio. Shanghai I-Mab announced it has achieved several clin...
Cancer specialist’s shares have nearly doubled in the last six months after it posted its first-ever profit and named two well-connected board members. I-Mab's shares have nearly doubled over the past six months on the major licensing deal, fundraising, and pending drug approva...
News, Short Squeeze, Breakout and More Instantly...
I-Mab Announces Leadership Transitions PR Newswire ROCKVILLE, Md. , July 15, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company" or "I-Mab"), a U.S.-based, global biotech company, announced today that the Board of Directors of the Company has appointed Mr. ...
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer PR Newswire ROCKVILLE, Md. , June 6 , 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercial...
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers PR Newswire I-Mab enters clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific anti...